Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.51M | 1.51M | 1.51M | 1.50M | 1.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.51M | 1.51M | 1.51M | 1.50M | 1.50M |
| Cost of Revenue | 18.63M | 25.21M | 25.49M | 22.76M | 20.47M |
| Gross Profit | -17.12M | -23.71M | -23.99M | -21.26M | -18.97M |
| SG&A Expenses | 6.71M | 6.51M | 5.70M | 5.72M | 5.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.33M | 31.73M | 31.20M | 28.48M | 26.24M |
| Operating Income | -23.83M | -30.22M | -29.69M | -26.98M | -24.74M |
| Income Before Tax | -22.38M | -28.83M | -25.48M | -24.97M | -16.25M |
| Income Tax Expenses | 2.00K | 2.00K | 2.00K | 2.00K | -- |
| Earnings from Continuing Operations | -22.38 | -28.83 | -25.48 | -24.97 | -16.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.38M | -28.83M | -25.48M | -24.97M | -16.25M |
| EBIT | -23.83M | -30.22M | -29.69M | -26.98M | -24.74M |
| EBITDA | -23.82M | -30.21M | -29.68M | -26.97M | -24.72M |
| EPS Basic | -0.73 | -0.94 | -0.83 | -0.81 | -0.45 |
| Normalized Basic EPS | -0.45 | -0.58 | -0.52 | -0.51 | -0.28 |
| EPS Diluted | -0.73 | -0.94 | -0.83 | -0.81 | -0.46 |
| Normalized Diluted EPS | -0.45 | -0.58 | -0.52 | -0.51 | -0.28 |
| Average Basic Shares Outstanding | 123.41M | 123.33M | 123.33M | 123.31M | 108.19M |
| Average Diluted Shares Outstanding | 123.41M | 123.33M | 123.33M | 123.31M | 108.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |